News
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
MIRA Pharmaceuticals presents preclinical results at Pain Therapeutics Summit showcasing that Ketamir-2 achieves 100% reversal of neuropathic pain. The innovative therapy targets NMDA receptors for enhanced efficacy -
-
-
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO
Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO, réduit les exacerbations et améliore la fonction respiratoire. Approbation suite à études de phase III -
COMMUNIQUÉ DE PRESSE
Coinsilium Group Limited: UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2024
Coinsilium Group Limited announces unaudited consolidated interim financial statements for the six-month period ended 30 June 2024. Revenue decreased, profit improved. Corporate agreements and investments made in Web3 projects. Directors' statement provided -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)
BayWa AG reports non-cash impairment losses of €222.2 million in Half-Year Financial Statements 2024 due to impairment tests. BayWa r.e. AG is the most affected subsidiary -
-
